View Older Stories View More Recent Stories

May 30, 2015 02:00PM TESARO and Merck to Collaborate on a Combination Study of Niraparib and KEYTRUDA(R) (Pembrolizumab)
May 29, 2015 02:06PM New Findings Show Durable Anti-Tumor Activity with KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Patients with Advanced Head and Neck Cancer, Regardless of PD-L1 Expression Status
May 29, 2015 02:05PM First Study Evaluating DNA Mismatch Repair as Genetic Guide for Immunotherapy Treatment with Merck’s KEYTRUDA® (pembrolizumab) Presented at 2015 ASCO Annual Meeting and Published in the New England
May 29, 2015 08:30AM Amgen And Merck Announce Expansion Of Collaboration To Support Studies Of Talimogene Laherparepvec In Combination With KEYTRUDA® (Pembrolizumab) In Patients With Head And Neck Cancer
May 28, 2015 04:30PM Merck Submits U.S. New Drug Application for Grazoprevir/Elbasvir, an Investigational Once-Daily, Single Tablet Combination Therapy, for Treatment of Chronic Hepatitis C Genotypes 1, 4, and 6 Infection
May 28, 2015 08:30AM Merck and NanoString Announce Clinical Research Collaboration to Develop an Immune-Related Gene Expression Assay for Use in the Development Program for KEYTRUDA® (pembrolizumab)
May 26, 2015 01:31PM Merck Announces Third-Quarter 2015 Dividend
May 26, 2015 06:33AM SIMPONI® (golimumab) Gains Positive Opinion from Committee for Medicinal Products for Human Use (CHMP) for the Treatment of Non-Radiographic Axial Spondyloarthritis
May 22, 2015 07:12AM Merck Receives Positive CHMP Opinion for KEYTRUDA® (pembrolizumab) for the Treatment of Advanced Melanoma
May 18, 2015 08:00AM Merck to Present at the UBS Global Healthcare Conference
May 13, 2015 05:00PM 2015 ASCO Annual Meeting: New Data in 10 Different Cancers from Merck’s Rapidly Expanding Immuno-Oncology Research Program for KEYTRUDA® (pembrolizumab) to be Presented
May 7, 2015 08:30AM Plexxikon and Merck to Collaborate on Combination Study Evaluating Investigational Immuno-oncology Regimen
Apr 28, 2015 05:50PM Market Wrap: Consumers Less Confident in April; Twitter Clipped on Q1 User Metrics; Biotechs Continue Slump
Apr 28, 2015 07:00AM Merck Announces First-Quarter 2015 Financial Results
Apr 27, 2015 06:30PM Merck Announces Publication of Pivotal Data from Phase 3 Clinical Studies of ZERBAXA™ (Ceftolozane/Tazobactam) in The Lancet and Clinical Infectious Diseases
Apr 27, 2015 05:00PM Merck Announces the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) Met Primary Endpoint
Apr 27, 2015 03:05PM Trading Radar for 4/28: Ford (F), Aetna (AET), Twitter (TWTR), GoPro (GPRO), Panera Bread (PNRA) Report
Apr 24, 2015 01:00AM Merck’s Pivotal Phase 3 C-EDGE Program Evaluating Grazoprevir/Elbasvir Shows High Sustained Virologic Responses Across Broad Range of Patients with Chronic Hepatitis C Virus Infection
Apr 23, 2015 03:30AM Merck Announces Results from Phase 2/3 Study of Investigational Chronic Hepatitis C Therapy Grazoprevir/Elbasvir in Patients with Advanced Chronic Kidney Disease
Apr 22, 2015 08:00AM Tim McGraw, Merck and the American Diabetes Association Challenge Americans with Type 2 Diabetes to Get to Their A1C Goal
Apr 21, 2015 08:30AM Merck Reaffirms Continued Commitment to Developing Innovative Medicines for the Treatment of Infectious Diseases at 25th Annual ECCMID Congress
Apr 20, 2015 08:00AM TetraLogic and Merck to Collaborate on the Evaluation of Birinapant in Combination With KEYTRUDA(R) (pembrolizumab) in Solid Tumors
Apr 20, 2015 08:00AM TetraLogic and Merck to Collaborate on the Evaluation of Birinapant in Combination with KEYTRUDA® (pembrolizumab) in Solid Tumors
Apr 19, 2015 12:45PM Early Findings with KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Patients with Advanced Pleural Mesothelioma Presented at AACR Annual Meeting
Apr 19, 2015 08:30AM Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with KEYTRUDA® (pembrolizumab) Presented at AACR Annual Meeting and Published in the New England Journal of Medicine
Apr 19, 2015 08:30AM KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, Demonstrates Superior Survival, Progression Free Survival and Overall Response Rate Compared to Ipilimumab an Anti-CTLA-4 Therapy...
Apr 19, 2015 08:00AM Merck Announces Submission of Supplemental Biologics License Application (sBLA) to U.S. FDA for KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cancer
Apr 14, 2015 01:30PM Phase III Trial of the Merck and NewLink Genetics Investigational Ebola Vaccine Initiated in Sierra Leone
Apr 8, 2015 07:30AM Advaxis and Merck Announce Initiation of Enrollment in the Phase 1/2 Study of ADXS-PSA in Combination With Anti-PD-1 Therapy, KEYTRUDA(R) (pembrolizumab), for the Treatment of Advanced Prostate Cancer
Apr 8, 2015 07:30AM Advaxis and Merck Announce Initiation of Enrollment in the Phase 1/2 Study of ADXS-PSA in Combination With Anti-PD-1 Therapy, KEYTRUDA(R) (pembrolizumab), for the Treatment of Advanced Prostate Cancer
Apr 8, 2015 07:00AM Grazoprevir/Elbasvir, Merck’s Investigational Chronic Hepatitis C Therapy, Granted FDA Breakthrough Therapy Designations; New Phase 2 and 3 Data in Multiple HCV Patient Types to be Presented at The
Apr 6, 2015 08:00AM Merck Receives 2015 ENERGY STAR Sustained Excellence Award from U.S. Environmental Protection Agency
Mar 31, 2015 08:00AM Syndax and Merck to Collaborate on Immuno-Oncology Study Evaluating Entinostat in Combination with KEYTRUDA® (pembrolizumab) in Lung Cancer and Melanoma
Mar 27, 2015 08:00AM Merck to Hold First-Quarter 2015 Sales and Earnings Conference Call on April 28
Mar 26, 2015 08:30AM Merck Announces Collaboration with the American Diabetes Association to Educate Adults with Diabetes About Increased Risk for Serious Diseases like Pneumococcal Pneumonia
Mar 24, 2015 05:00PM Merck Announces New $10 Billion Share Repurchase Program
Mar 24, 2015 08:30AM Merck’s Pivotal KEYNOTE-006 Study in First-Line Treatment for Advanced Melanoma Met Co-Primary Endpoints and Will be Stopped Early
Mar 20, 2015 10:02AM Award-Winning Actress S. Epatha Merkerson and Merck Challenge African Americans with Type 2 Diabetes to Get to Their Goals
Mar 18, 2015 04:19PM New Data Investigating Merck’s KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cancer and Mesothelioma to Be Presented in Clinical Trials Plenary Session at AACR 2015
Mar 16, 2015 03:30PM New Analysis from Investigational IMPROVE-IT Study Shows VYTORIN® (ezetimibe/simvastatin) Reduced Total (Initial and Recurrent) Cardiovascular Events More than Simvastatin Alone in Patients Presentin
Mar 13, 2015 04:02PM Merck Provides Regulatory Update on Investigational Medicine Sugammadex Injection
Mar 10, 2015 08:01PM KEYTRUDA® (pembrolizumab) is First Medicine to be Made Available to Patients Through U.K. Early Access to Medicines Scheme (EAMS) for Advanced Melanoma
Mar 10, 2015 08:00AM Merck to Present at the Barclays Global Healthcare Conference
Mar 5, 2015 08:00AM Two New Post-Hoc Analyses of TRA 2°P TIMI 50 Study Showed ZONTIVITY® (vorapaxar) Added to Aspirin and/or Clopidogrel Reduced Acute Limb Ischemia and Peripheral Revascularizations, Respectively, in C
Dec 8, 2014 05:21PM Cubist Pharma (CBST) Declines: Traders Discuss Patent Dispute vs Hospira (HSP)
Nov 24, 2014 07:30AM Merck and NewLink Genetics Enter Into Licensing and Collaboration Agreement for Investigational Ebola Vaccine
Oct 27, 2014 05:30PM Market Wrap: Valeant Lifts Allergan Bid; Twitter's Ho-Hum Q3 Report; Tesla Slumps on Sales Speculation
Oct 24, 2014 03:13PM Trading Radar for 10/27: Twitter (TWTR), Buffalo Wild Winds (BWLD), Crocs (CROX), Huntsman (HUN) Report
Oct 2, 2014 10:46AM Notable Analyst Rating Changes 10/2: (TWTR) (ADSK) (AKS) Upgraded; (JPM) (ENPH) (ETN) Downgraded
Jul 29, 2014 05:37PM Market Wrap: Home Prices Gain at Slower Pace; Twitter Soars in Q2; Ford Opts for Apple
View More Recent Stories View Older Stories